Genmab A (GMAB) Cash & Equivalents (2018 - 2026)

Genmab A (GMAB) has reported Cash & Equivalents for 9 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 15.97% year-over-year to $1.5 billion; the trailing twelve-month figure through Jun 2026 stood at $1.5 billion (up 15.97% YoY), and the FY2025 full-year result was $1.7 billion, up 24.28% from the prior year.
• Cash & Equivalents fell to $1.5 billion in Q2 2026 per GMAB's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.7 billion in Q4 2025 and bottomed at $367.5 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 87.68% in 2022, then soared 108.36% in 2025.
• Over 5 years, Cash & Equivalents stood at $824.0 million in 2022, then surged by 69.5% to $1.4 billion in 2023, then slumped by 34.33% to $917.2 million in 2024, then soared by 86.98% to $1.7 billion in 2025, then fell by 12.36% to $1.5 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.5 billion, $1.5 billion, and $1.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.